MarketCap
Facebook
X
Telegram
Concert Pharmaceuticals Net Income | CNCE
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Concert Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -80.1 M | -74.8 M | -20.5 M | -20.8 M | -6.07 M | -50.7 M | 24.2 M | -31.7 M | -6.06 M | -20.4 M | -11.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.2 M | -80.1 M | -27.1 M |
Quarterly Net Income Concert Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -28.9 M | -23.5 M | -37.7 M | - | -26.7 M | 5.42 M | -22.7 M | -22.4 M | -18.9 M | -13 M | -20.5 M | -20.5 M | -17.2 M | -18.7 M | -21.8 M | -20.8 M | -17.4 M | -13.3 M | -4.46 M | -6.07 M | 128 M | -26.4 M | -13.3 M | -12 M | -11.4 M | -13.4 M | -13.9 M | 684 K | -8.55 M | 41 M | -9 M | -8.93 M | -7.83 M | -7.99 M | -6.95 M | -5.92 M | -7.13 M | 8.76 M | -1.78 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 128 M | -37.7 M | -8.55 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
59 M | $ 76.31 | 0.69 % | $ 5.66 B |  USA |
 |
Kodiak Sciences
KOD
|
-230 M | $ 93.81 | 0.32 % | $ 4.99 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
-196 M | $ 0.67 | 1.51 % | $ 7.33 K | USA |
 |
Keros Therapeutics
KROS
|
87 M | $ 11.52 | 1.41 % | $ 429 M | USA |
 |
Krystal Biotech
KRYS
|
205 M | $ 334.85 | 3.9 % | $ 9.69 B | USA |
 |
Kura Oncology
KURA
|
-279 M | $ 10.62 | 0.09 % | $ 931 M | USA |
 |
Kymera Therapeutics
KYMR
|
311 M | $ 109.85 | 2.29 % | $ 9.28 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-20.7 M | $ 9.35 | 0.86 % | $ 143 M |  Australia |
 |
Lineage Cell Therapeutics
LCTX
|
-63.5 M | $ 0.93 | 2.73 % | $ 214 M | USA |
 |
Legend Biotech Corporation
LEGN
|
-297 M | $ 18.77 | 1.1 % | $ 6.92 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
124 M | $ 306.77 | 1.26 % | $ 5.93 B | USA |
 |
Longeveron
LGVN
|
-22.7 M | $ 2.51 | 0.39 % | $ 44.1 B | USA |
 |
Eli Lilly and Company
LLY
|
20.6 B | $ 1 143.12 | 0.02 % | $ 1.03 T | USA |
 |
Lipocine
LPCN
|
-9.63 M | $ 2.07 | 0.98 % | $ 11.3 M | USA |
 |
Liquidia Corporation
LQDA
|
-68.9 M | $ 27.64 | 2.32 % | $ 2.38 B | USA |
 |
Larimar Therapeutics
LRMR
|
-166 M | $ 2.86 | 1.75 % | $ 238 M | USA |
 |
Lantern Pharma
LTRN
|
-17.1 M | $ 0.94 | 9.3 % | $ 10.2 M | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
-50.3 M | $ 1.74 | 0.82 % | $ 632 M | USA |
 |
Mustang Bio
MBIO
|
-1.92 M | $ 0.46 | 1.16 % | $ 2.26 M | USA |
 |
Moleculin Biotech
MBRX
|
-33.6 M | $ 0.48 | 0.42 % | $ 569 K | USA |
 |
Seres Therapeutics
MCRB
|
5.7 M | $ 2.85 | 0.34 % | $ 25.2 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
-288 M | $ 493.62 | 0.1 % | $ 11.1 B | USA |
 |
MediWound Ltd.
MDWD
|
-9.2 M | $ 13.51 | 0.22 % | $ 368 M |  Israel |
 |
Mesoblast Limited
MESO
|
-102 M | $ 14.22 | 0.99 % | $ 17.2 B | Australia |
 |
MacroGenics
MGNX
|
-74.6 K | $ 3.77 | 5.31 % | $ 238 M | USA |
 |
MeiraGTx Holdings plc
MGTX
|
-114 M | $ 10.92 | 1.2 % | $ 878 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
-23.4 M | $ 81.43 | 0.07 % | $ 4.09 B | USA |
 |
Milestone Pharmaceuticals
MIST
|
-63.1 K | $ 0.78 | 0.25 % | $ 82.9 M |  Canada |
 |
MannKind Corporation
MNKD
|
5.86 M | $ 3.82 | 0.53 % | $ 1.17 B | USA |
 |
MediciNova
MNOV
|
12 M | $ 1.76 | 0.28 % | $ 86.4 M | USA |
|
Monopar Therapeutics
MNPR
|
-13.7 M | $ 78.29 | 0.41 % | $ 580 M | USA |
 |
Mereo BioPharma Group plc
MREO
|
-164 M | $ 0.39 | 2.16 % | $ 311 M |  Britain |
 |
Merck & Co.
MRK
|
18.3 B | $ 139.54 | 0.34 % | $ 349 B | USA |
 |
Marker Therapeutics
MRKR
|
-12.2 M | $ 1.06 | 0.95 % | $ 16.2 M | USA |
 |
Moderna
MRNA
|
-2.82 B | $ 203.21 | 6.95 % | $ 79 B | USA |
 |
Maravai LifeSciences Holdings
MRVI
|
-131 M | $ 8.52 | 7.85 % | $ 1.23 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
-10.3 M | $ 2.82 | 6.82 % | $ 15.4 M | USA |
 |
RAPT Therapeutics
RAPT
|
-130 M | - | - | $ 2.36 B | USA |
 |
Neurocrine Biosciences
NBIX
|
479 M | $ 144.21 | 0.72 % | $ 14.3 B | USA |
 |
Nanobiotix S.A.
NBTX
|
-24 M | $ 25.1 | 0.16 % | $ 1.2 T |  France |
 |
NuCana plc
NCNA
|
-29.4 M | $ 1.06 | 2.75 % | $ 11.9 B | Britain |
 |
Minerva Neurosciences
NERV
|
-293 M | $ 3.32 | 1.22 % | $ 28.1 M | USA |
 |
Nektar Therapeutics
NKTR
|
-164 M | $ 42.22 | 2.2 % | $ 712 M | USA |
 |
Nkarta
NKTX
|
-104 M | $ 2.53 | 0.59 % | $ 187 M | USA |
 |
NanoViricides
NNVC
|
-8.22 M | $ 1.45 | 13.28 % | $ 29.3 M | USA |
 |
Nurix Therapeutics
NRIX
|
-264 M | $ 22.88 | 0.09 % | $ 1.98 B | USA |
|
Nuvation Bio
NUVB
|
-205 M | $ 4.95 | 1.07 % | $ 1.69 B | USA |
 |
Novavax
NVAX
|
440 M | $ 12.56 | 20.08 % | $ 2.03 B | USA |
 |
Novo Nordisk A/S
NVO
|
102 B | $ 37.54 | 0.59 % | $ 167 B |  Danmark |
 |
Novartis AG
NVS
|
14 B | $ 140.93 | 0.01 % | $ 273 B |  Schweiz |